Biden Admin Has No Record Of Marijuana Letter Cited By DEA Head In Congressional Testimony

August 11, 2023 ·

The U.S. Department of Health and Human Services (HHS) says it has no record of a letter from the White House regarding President Joe Biden’s marijuana scheduling review directive, seemingly contradicting what the head of the Drug Enforcement Administration (DEA) recently testified to lawmakers.

At a House Judiciary Committee hearing last month, DEA Administrator Anne Milgram told Rep. Matt Gaetz (R-FL) that the president “had sent a letter to the secretary of HHS and to the attorney general to ask for the scheduling—descheduling process to begin.”

Attorney Matt Zorn filed a Freedom of Information Act (FOIA) request for a copy of that letter, and HHS sent him a response last week stating that it “conducted a search” that determined “there are no records responsive to your request.”

In an open letter published on his “On Drugs” Substack, Zorn implored Gaetz to “follow up with DEA” about the potential document, which could shed light on the opaque administrative process that is ongoing as federal agencies contemplate the appropriateness of marijuana being classified as a strictly illegal Schedule I drug under the Controlled Substances Act (CSA).

It is possible, of course, that Milgram misspoke when she described a letter from the president. Marijuana Moment reached out to DEA for clarification, but a representative did not respond by the time of publication.

But the question of the technical origins and processing of the scheduling review directive remain of significant interest within the cannabis space and broader public. Both the Department of Justice, which DEA falls under, and HHS appeared to have coordinated statements prepared on the day that Biden called for the review, and issued a mass pardon for people who’ve committed federal marijuana possession offenses. That would suggest that the agencies received some kind of advance notice before the president made the public declaration.

“There are aspects of this process that the public doesn’t need to, and probably shouldn’t, be privy to,” Zorn told Marijuana Moment on Thursday. “But the basic milestones like the document that starts the process, we should be able to examine. Congress should have it, the public should have it. That’s not asking too much.”

While HHS said its internal search for documents responsive to the FOIA request came up dry, it’s possible that the date range of the request—from September 1, 2022 to March 1, 2023—was too narrow. Biden publicly issued the directive and pardons on October 6, 2022, but it could be the case that the White House began notifying agencies about the future action months before he made the announcement.

The current status of the administrative review into cannabis scheduling is unclear, though HHS Secretary Xavier Becerra did tell Marijuana Moment in June that agencies are aiming to complete their work by the end of the year. Milgram also told Gaetz during last month’s hearing that she would ask HHS for an update on the timing of their review.

The process starts with a scientific review into marijuana by HHS—and specifically the Food and Drug Administration (FDA) under HHS. Once that’s complete, the department will forward its findings and scheduling recommendation to DEA, which will then conduct its own eight-step review before making a final decision. The recommendation from HHS is not binding, as DEA has primary jurisdiction over the CSA and could theoretically dismiss the health agency’s position.

Meanwhile, the White House drug czar said in separate congressional testimony recently that the president’s marijuana pardons and scheduling directive last year are part of an effort to create cohesive cannabis policy within a patchwork of state legalization models.

Congressional Cannabis Caucus co-chair Rep. Earl Blumenauer led a letter to Becerra and Attorney General Merrick Garland in March, alongside 15 other bipartisan members of Congress, demanding transparency in the cannabis scheduling review. (Full Story)

In category:Politics
Next Post

DEA Chief Seeks Clarity on Cannabis Rescheduling

U.S. Drug Enforcement Administration Administer Anne Milgram told lawmakers that she will seek clarity from the Department of Health and Human Services on the timeline for the Biden administration’s review of the scheduling of cannabis under the Controlled Substances Act.…
Previous Post

Los Angeles mayor expected to pick new chief for city’s cannabis agency

Los Angeles Mayor Karen Bass is shaking up leadership at several city agencies, including an expected management overhaul at L.A.’s cannabis regulatory agency – which oversees a roughly $1 billion marijuana market. A listing for an executive director for the Department of…
Random Post

VA And Defense Department Oppose Medical Marijuana For PTSD, But Take Neutral Position On Psychedelics As Research Continues

The U.S. Department of Veterans Affairs (VA) and Department of Defense (DOD) are strongly against the use of marijuana for the treatment of post-traumatic stress disorder (PTSD)—but they’re taking a neutral position on psychedelics like psilocybin and LSD, simply saying…
Random Post

Study: Cannabis Has Positive Impact on Sexual Quality

A study published last month in the Journal of Cannabis Research suggests that cannabis use has a positive impact on sexual quality. In the study, an online survey of 811 people, more than 70% of respondents reported increased sexual desire and orgasm…
Random Post

New York Cannabis Farmers Markets in Limbo

New York Gov. Kathy Hochul’s office appears to have put an indefinite hold on an idea floated in May by state regulators for marijuana farmers markets, a plan popular with growers because it would have provided a safety valve for hundreds…
Random Post

Engineering Psychedelics: $22M Pool For Clinical Trials Of Compounds Targeting CNS Disorders

NYC and Cambridge-based Empyrean Neuroscience Inc. is a new genetic engineering company developing neuroactive compounds for neuropsychiatric and neurological disorders launching with a $22 million Series A financing. The company’s CEO is long-time biotech executive Dr. Usman “Oz” Azam, joined by Dr. Fred Grossman as chief medical officer.…